Late-Breaking Trials Picked For Spring ACC meeting
This article was originally published in The Gray Sheet
Executive Summary
The top trial reports at the American College of Cardiology's signature annual event will address transcatheter aortic valve replacements, atrial fibrillation ablation, heart-failure neurostimulation treatments, and more.
You may also be interested in...
Lilly Signs Deals With Dexcom, Glooko, myDiabby, Roche For Diabetes Management Solutions
Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.
Three IPOs, Three SPAC Mergers, But One Company Opted Out
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.
Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.